Questions research teams usually ask before bringing in outside help.

What does a clinical trial site operations consultant actually do?

A site operations consultant helps a research team diagnose and improve the work required to execute a protocol at the site. Depending on the problem, that can include feasibility and study start-up, patient enrollment and participant flow, monitoring follow-up and CAPA, inspection readiness, portfolio operations, or research data workflow.

Merindale focuses on defined operating problems rather than broad transformation programs.

Who is the best fit for Merindale?

Merindale is designed for research institutions, site networks, research sites, principal investigators, and sponsor/CRO partners that need experienced site-side support around a specific execution problem. Our strongest clinical depth is in oncology and genitourinary research, with broader applicability to complex clinical trial site operations.

Where is Merindale based, and do you work outside Atlanta?

Merindale is based in Atlanta, Georgia. We welcome remote and on-site engagements across Georgia and the Southeast, with the delivery model matched to the work. Some projects can be completed almost entirely through remote review and working sessions; others benefit from on-site observation, stakeholder sessions, or workflow mapping.

For more detail, see our Atlanta & Southeast clinical trial consulting page.

Is Merindale a CRO?

No. Merindale is an independent clinical research consulting practice, not a full-service contract research organization. We do not present ourselves as a substitute for global trial management, full-service monitoring, central laboratory, pharmacovigilance, or sponsor-level operational infrastructure.

Our role is closer to the site: understanding how a protocol becomes day-to-day work and helping teams improve the handoffs, controls, measurements, and participant pathway around it.

Can Merindale work with sponsors or CROs, or only research sites?

Merindale can work with sponsors and CRO partners when the need is genuinely site-centered—for example, understanding feasibility quality, activation friction, enrollment loss points, monitoring follow-up, or operational patterns across sites. The scope should remain within the experience we can credibly deliver.

What does the first engagement usually look like?

We prefer to begin with one defined problem: one study, one startup path, one enrollment funnel, one quality issue, or one portfolio constraint. The first step is to agree on the question, review the available evidence, speak with the people closest to the work, and determine whether the issue is narrow enough to address practically.

Our Diagnose → Redesign → Transfer approach is designed to leave the internal team with a system it can continue to run.

How collaborative is the work?

Very. Site operations live in details that outside consultants cannot see from a slide deck alone. We expect to work with coordinators, investigators, managers, regulatory or data staff, and other relevant owners to understand how work actually moves.

We do not want a recommendation to succeed because Merindale is present. We want the people who own the process to understand it, improve it, and be able to sustain it after the engagement ends. Our Professional Standards describe that expectation in more detail.

What information does Merindale need to diagnose a site problem?

It depends on the scope, but useful evidence may include activation timelines, feasibility assumptions, screening or enrollment logs, monitoring action logs, workload data, process maps, status trackers, query aging, or role ownership. We prefer the minimum information necessary to answer the question.

Initial website inquiries should not include patient-identifiable information or PHI. See our Data Handling & Security statement.

Do we need to share patient-level data?

Not for an initial conversation, and not automatically for an engagement. Many operating problems can be diagnosed with aggregated, de-identified, process-level, or metadata views. If a project genuinely requires access to sensitive or regulated information, the contractual, technical, and access controls should be established before that information is shared.

How does Merindale measure whether an engagement worked?

The measure should match the problem. Examples might include shorter aging at a startup handoff, clearer ownership, improved identification-to-approach visibility, fewer overdue monitoring actions, faster closure of repeat findings, reduced query aging, or a portfolio review that surfaces exceptions earlier.

We do not promise a specific enrollment number, activation date, revenue result, or inspection outcome. Clinical trial performance depends on protocol design, patient population, institutional processes, sponsor decisions, staffing, competing studies, and other factors outside any consultant's control.

What if Merindale is not the right fit?

We would rather say that early. If the need is primarily sponsor-level global trial management, regulatory legal advice, medical decision-making, full-service CRO execution, or another specialty outside our experience, we will not force it into a Merindale service package.

Where should we start if we are not sure what the problem is?

Start with the symptom and the evidence you already have. Tell us what is delayed, underperforming, repeating, hard to control, or creating unnecessary work. You can also review our guides on clinical trial site feasibility, GU trial screening and enrollment, monitoring findings and CAPA, and clinical trial site workflow handoffs.